Reaferon-EU-Lipint (Interferon alpha-2b)

1 ampoule contains:

Active substance:

 interferon alfa-2a;

Excipients:

sodium chloride,

sodium hydrogen phosphate dodecahydrate,

sodium dihydrogen phosphate dihydrate,

lecithin or C100 lipoid,

cholesterol,

tocopherol (vitamin E),

lactose.

Reaferon EC Lipint - an antiviral and immunomodulating drug, is human recombinant interferon alfa-2b, enclosed in liposomes and lyophilized.

Viral hepatitis B, C, D, viral, viral, bacterial and mycoplasma meningoencephalitis, viral conjunctivitis, keratoconjunctivitis, keratitis, keratouveitis, stage IV kidney cancer, hairy cell leukemia, malignant skin lymphomas, squamous cell carcinoma, cellulose cell carcinoma, , multiple sclerosis, lymphoblastic leukemia in children, respiratory laryngeal papillomatosis.

• Hairy cell leukemia, chronic myeloid leukemia;
• chronic active hepatitis B, hepatitis C. Kaposi's sarcoma, melanoma;
• genital warts.

Reaferon-EU-Lipint is contraindicated in pregnancy, lactation and in children under 2 years of age.

• hypersensitivity to the drug Reaferon-EC-Lipint;
• severe impaired liver or kidney function;
• severe cardiovascular disease;
• epilepsy.

When used according to the indications in recommended doses, the drug does not have side effects.

However, given that its active ingredient is recombinant interferon, which causes flu-like side effects upon parenteral administration, caution is required when prescribing the drug to individuals with individual intolerance to interferon preparations.

• flu-like condition;
• nausea, vomiting, diarrhea;
• sensation of "crawling", trembling limbs;
• violation of the blood picture;
• impaired liver function;
• dizziness, drowsiness;
• decrease or increase in blood pressure, arrhythmias.

Interferon alfa-2b is able to reduce the activity of isoenzymes of cytochrome P450 and, therefore, with the simultaneous use, affect the metabolism of cimetidine, phenytoin, dipyridamole, theophylline, diazepam, propranolol, warfarin, and some cytostatics.

The drug can enhance the neurotoxic, myelotoxic or cardiotoxic effect of drugs prescribed earlier or simultaneously with it.

The drug is intended for oral administration. Immediately before use, add 1-2 ml of distilled or chilled boiled water to the contents of the vial. When shaking for 1 to 5 minutes, a uniform suspension should form.

In acute hepatitis B, the drug is taken 30 minutes before meals according to the following scheme: adults and children of school age are prescribed 1 million ME 2 times / day for 10 days; children of preschool age (from 3 to 7 years) - 500 thousand ME 1 time / day for 10 days or after control biochemical blood tests for a longer time (until complete clinical recovery).

In chronic hepatitis B in active and inactive replicative forms, as well as in chronic hepatitis B associated with glomerulonephritis, the drug is taken 30 minutes before meals according to the following scheme: 1 million ME is prescribed for adults and children of school age 2 times / day for 10 days and then proceed to the introduction of 1 time at night every other day for 1 month; children of preschool age (from 3 to 7 years) - 500 thousand ME 2 times / day for 10 days and then switch to the introduction of 500 thousand ME 1 time per night every other day for 1 month.

When carrying out specific immunotherapy, the drug is taken in the morning, 30 minutes after a meal, according to the following scheme: for allergic rhinoconjunctivitis, adults are prescribed 500 thousand ME daily for 10 days (course dose - 5 million ME); with atopic bronchial asthma for adults - 500 thousand ME 1 time / day for 10 days, and then 500 thousand ME every other day for 20 days. The total duration of treatment is 30 days.

For the prevention of influenza and acute respiratory infections, the drug is taken 30 minutes before meals; adults and children over 15 years of age are prescribed 500 thousand ME 2 times a week for 1 month during the rise in incidence; children from 3 to 15 years old - 250 thousand ME 2 times a week for 1 month during the rise in incidence. In the treatment of influenza and acute respiratory infections, adults and children over 15 years of age - 500 thousand ME 2 times / day for 3 days; children from 3 to 15 years old - 250 thousand ME 2 times / day for 3 days.

With the complex treatment of urogenital infections, adults are prescribed 500 thousand ME 2 times / day for 10 days.

A solution of Reaferon-EC-Lipint should be prepared immediately before use.

In the course of treatment with Reaferon-EU-Lipint, a systematic monitoring of the function of the bone marrow, liver, and kidneys is necessary, as well as regular neurological examination of patients.

With fever and headaches Reaferon-EU-Lipint effective.

Lyophilisate for oral suspension.